SpecCheck vs Veeva Systems
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF optical industry B2B platform unifying eyewear ordering, tracking, and billing for eye care professionals; YC W23 $3.82M Initialized Capital seed targeting $68.3B US optical market fragmented across doctors, labs, and insurers.
About
SpecCheck is a San Francisco-based optical industry B2B platform — backed by Y Combinator (W23) with $3.82 million raised including a $3.7 million seed round led by Initialized Capital in October 2023 — providing eye care professionals and optical businesses with a unified prescription eyewear ordering, tracking, and billing system that connects optometrists, opticians, and optical labs in a single workflow to eliminate the manual coordination, phone calls, and paper-based processes that dominate the $68.3 billion US optical industry. Founded in 2023, SpecCheck addresses the fragmentation in optical dispensing workflow where prescriptions travel between eye doctors, dispensing opticians, and fulfillment labs through a mix of fax, phone, and disconnected software systems.
Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.
About
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.